In a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on Aligos Therapeutics (ALGS – Research Report), with a price target of $7.00. The company’s shares closed last Tuesday at $2.90, close to its 52-week low of $2.11.
According to TipRanks.com, Ruiz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.4% and a 41.7% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.
Currently, the analyst consensus on Aligos Therapeutics is a Moderate Buy with an average price target of $9.00, implying a 221.4% upside from current levels. In a report issued on March 11, Cowen & Co. also maintained a Buy rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Aligos Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.54 million and GAAP net loss of $33.12 million. In comparison, last year the company had a GAAP net loss of $34.42 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).
Read More on ALGS:
